Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Leukemia, Myeloid, Acute 11Multiple Myeloma 7Sarcoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Ovarian Neoplasms 2Neurofibrosarcoma 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Glioblastoma 2Congenital Abnormalities 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Adenocarcinoma 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma, Ewing 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Rhabdoid Tumor 1

Interventions

Cisplatin 17pembrolizumab 12Radiotherapy 11Nivolumab 7Cetuximab 6Paclitaxel 5fludarabine 4aldesleukin 4Radiation 4Interleukin-2 4Docetaxel 4Cyclophosphamide 4olaparib 3fludarabine phosphate 3Carboplatin 3talimogene laherparepvec 2atezolizumab 2Taxes 2Sorafenib 2Fluorouracil 2Erlotinib Hydrochloride 2Drug Therapy 2Capecitabine 2Bortezomib 2130-nm albumin-bound paclitaxel 2vandetanib 1tozuleristide 1tilsotolimod 1testosterone enanthate 1temoporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Squamous Cell × selinexor × Clear all
NCT01607905 2023-01-26

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Karyopharm Therapeutics Inc

Phase 1 Completed
192 enrolled 29 charts
CNSDermatologicGastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Glioblastoma, Melanoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡